TRD Experts Push for Remission, Not Just Response

The Shift From 'Less Bad' to Actually Better

A recent clinical discussion published in Psychiatric Times (April 2026) is drawing attention for its pointed message to clinicians treating treatment-resistant depression (TRD): stopping at partial improvement is no longer acceptable. The piece emphasizes that the goal of care should be full remission — not simply a reduction in symptom severity — and that providers need to more aggressively tailor treatment to each patient's priorities and tolerability profile.

This framing matters because TRD, broadly defined as depression that has failed to respond to at least two adequate antidepressant trials, affects an estimated 30% of people diagnosed with major depressive disorder. For this population, the therapeutic journey is often long, demoralizing, and marked by incremental gains that don't add up to a meaningful recovery. The clinical consensus emerging from this piece challenges that resigned acceptance of partial improvement.

Where Ketamine Fits in the TRD Landscape

Low-dose ketamine — whether administered intravenously, intranasally via esketamine (Spravato), or through emerging oral and sublingual formulations — has become one of the more consequential tools in the TRD toolkit precisely because it operates through a fundamentally different mechanism than conventional antidepressants. Rather than modulating serotonin or norepinephrine over weeks, ketamine works on glutamate pathways and produces rapid antidepressant effects, often within hours to days of the first dose.

That speed is clinically significant. For a patient who has cycled through multiple failed medication trials over months or years, a treatment that can produce measurable relief quickly changes the calculus of care. The Psychiatric Times discussion reinforces that when the target is remission rather than partial response, rapid-acting options become more strategically important — particularly in the acute phase of treatment when engagement and hope are fragile.

However, the same clinical conversation that elevates ambition also demands nuance. Ketamine's evidence base, while growing, is still maturing. Most controlled trials have examined short-term outcomes, and questions around optimal dosing intervals, long-term maintenance schedules, and who is most likely to sustain benefit remain active areas of research. This is not a reason to avoid ketamine — it is a reason to approach it with clear expectations and ongoing monitoring.

Balancing Efficacy Targets With Side Effect Realities

One of the more practically useful threads in the Psychiatric Times piece is its emphasis on balancing efficacy goals with individual tolerability and patient priorities. This is especially relevant for ketamine patients, where side effects — including dissociation, transient increases in blood pressure, and the theoretical risk of dependence with frequent use — are real considerations that vary meaningfully across individuals.

At low doses used in depression treatment, ketamine is generally well-tolerated, but 'generally' is not 'universally.' Some patients find the dissociative experience disorienting or distressing, particularly at the outset. Others adapt quickly and report that the altered state is mild or even therapeutically meaningful. Dosing decisions — including the starting dose, titration pace, and spacing between sessions — should account for both the patient's symptom burden and their subjective experience of the treatment itself.

The push toward remission as a standard also has implications for maintenance. Achieving remission is one goal; sustaining it is another. For many ketamine patients, the antidepressant effect begins to fade within days to weeks after an acute series, which is why maintenance dosing — typically less frequent infusions or intranasal sessions spaced out over months — has become a central part of clinical protocols. Providers aiming for durable remission need to plan for this phase explicitly, not treat it as an afterthought.

What Patients Should Take From This

The clinical conversation reflected in the Psychiatric Times piece is a meaningful signal that the standard of care for TRD is being actively renegotiated — upward. That's encouraging. It also means patients are increasingly empowered to advocate for more ambitious treatment goals rather than accepting plateau-level improvement as the ceiling.

For those currently in or considering low-dose ketamine treatment, a few practical implications follow. First, clarity on your treatment target matters: are you and your provider aligned on what remission looks like for you, functionally and symptomatically? Second, maintenance is not optional for most TRD patients — building a realistic maintenance plan into your care from the beginning reduces the likelihood of relapse after an initial positive response. Third, side effect tolerance is a legitimate variable in treatment decisions, and adjusting dose or delivery format is appropriate if tolerability is limiting your ability to stay in treatment.

The evidence base for ketamine in TRD continues to develop. The field does not yet have long-term randomized trial data on multi-year maintenance outcomes, and individual variation in response remains difficult to predict in advance. But the directional evidence is consistent enough that ketamine now appears in expert clinical discussions as a serious option — not a last resort, and not a novelty, but a legitimate tool for patients whose depression has not responded to conventional approaches.

Read the original clinical discussion at Psychiatric Times.